OMER - Omeros: PDUFA Delay Presents An Opportunity July, 03 2021 10:45 AM Omeros Corporation Omeros has had its PDUFA delayed by three months. The reason is that the FDA needs additional time to review data it had asked for. This represents a buying opportunity. For further details see: Omeros: PDUFA Delay Presents An Opportunity